A study of novel anti-cancer agents in patients with previously untreated NSCLC

Trial Identifier: D933IC00001
Sponsor: AstraZeneca
Start Date: December 2018
Primary Completion Date: May 2023
Study Completion Date: March 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AT Salzburg, AT, 5020
AT Wien, AT, 1140
BE Edegem, BE, 2650
ES Barcelona, ES, 08025
ES Barcelona, ES, 8003
ES Madrid, ES, 28034
ES Madrid, ES, 28041
ES Sevilla, ES, 41013
KR Cheongju-si, KR, 28644
KR seoul, KR, 06351
KR Seoul, KR, 05505
KR Seoul, KR, 03722
KR Seoul, KR, 110-744
PL Bialystok, PL, 15-027
PL Bydgoszcz, PL, 85-796
PL Gdańsk, PL, 80-214
PL Grudziądz, PL, 86-300
PL Łódź, PL, 90-302
PL Olsztyn, PL, 10-357
PL Tomaszów Mazowiecki, PL, 97-200
PL Warszawa, PL, 02-781
PL Wroclaw, PL, 53-413
RU Krasnoyarsk, RU, 660133
RU Moscow, RU, 115478
RU Saint Petersburg, RU, 197758
RU Sankt-Peterburg, RU, 197758
RU St.Petersburg, RU, 191014
TH Bangkok, TH, 10330
TH Bangkok, TH, 10700
TH Chiang Mai, TH, 50200
TH Hat Yai, TH, 90110
TW Kaohsiung, TW, 807
TW Taichung, TW, 40705
TW Taichung City, TW, 402
TW Tainan City, TW, 70403
TW Taipei, TW, 10002
TW Taipei, TW, 235
TW Taipei, TW, 112
TW Taoyuan, TW, 333
US, IA Iowa City, IA, US, 52242
US, PA Pittsburgh, PA, US, 15212
US, TN Nashville, TN, US, 37203